Sun Pharma Leadership Changes & USFDA Inspection Update

  Published 9 months ago

Sun Pharma announces MD change, Dilip Shanghvi to executive chairman, Kirti Ganorkar appointed; USFDA issues Form 483 after inspection.

  • Dilip Shanghvi transitions to executive chairman, focusing on specialty portfolio growth and strategic oversight.
  • Kirti Ganorkar, a 27-year veteran, led India business growth, expanded specialty drugs, and global markets.
  • USFDA inspects Gujarat facility, issues Form 483 with 8 observations post June 2025 inspection.
You might like these

Hexaware Sees Modest Q2 Growth

Amazon Prime Day 2024: Luxury Beauty Fights Tariffs

Rupee Near Record Low, Tracks Oil, Asia FX

Arkade Developers Expands in Mumbai's Goregaon with New Project

Tech Lawyer Neel Chatterjee Joins King & Spalding

SBI Life’s Strong H1 FY26 Growth

Polycab Q1 Profit Jumps 50%

News that matters the most ⚡